Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Carissa Chu discusses her Prostate Cancer Foundation Young Investigator Award work on STEAP1-targeted bispecific T-cell engagers. Dr. Chu explains that STEAP1, a six-transmembrane surface protein, is ...

Men with prostate cancer face considerable cardiovascular (CV) comorbidity. Androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) elevate this risk, yet no ...

(UroToday.com) In this presentation, Dr. Fred Saad presented results of the PROpel study. PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as ...

ESMO 2024, Prostate Cancer, transdermal estradiol, LHRH agonists, Transdermal Estradiol Versus LHRH Agonists, Androgen Suppression in M0 Prostate Cancer, STAMPEDE trial.

(UroToday.com) The 2022 GU ASCO Annual meeting included a prostate cancer session highlighting work from Dr. Zachery R. Reichert and colleagues presenting results of the TRAP trial, targeting ...

(UroToday.com) In the Proffered Paper Session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Andrew Armstrong presented the final overall survival ...

(UroToday.com) The 2022 American Urological Association Annual Meeting included a prostate cancer session featuring work from Dr. Mohammad Siddiqui and colleagues presenting results of their study ...

(UroToday.com) Treatment with platinum-based chemotherapy and program death ligand 1 (PD-L1) immune checkpoint inhibitor has been shown to have a modest objective response rate (ORR) and limited ...

(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 Virtual Meeting, Dr. Simon Chowdhury presented results of outcomes in high and low-volume disease ...